Condition
Overweight
Obesity
Locations
United States
Start date
01/10/2025
Identifiers
Trial ID NN9662-8110,
NCT number NCT07184632,
Eudract number Not Available
NCT number NCT07184632,
Eudract number Not Available
Summary
This study tests how well different doses of the medicine NNC0662-0419 help people living with overweight or obesity. The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating people living with overweight or obesity. There are 2 study treatments in this study, participants will get either NNC0662-0419, the treatment being tested or placebo, a treatment that has no active medicine in it. NNC0662-0419 is a new medicine which cannot be pre-scribed by doctors but has previously been tested in humans.
Trial Overview:
Treatment
DRUG: NNC0662-0419
DRUG: Placebo
Study type
INTERVENTIONAL
Trial duration
Oct 01 2025 - Dec 01 2026
Participants
220
Phase
II
Are you eligible?
Gender
Male and female
Age
18 to 65 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.